{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20","upperLimit":"100","value":"54"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Complement CH50 is a blood test that helps us determine whether protein abnormalities and deficiencies in the complement system are responsible for any increase in autoimmune activity.","dispersionType":"Full Range","groups":[{"description":"Ofatumumab will be infused intravenously on day 1 (300 mg initial dose), followed one week later by 2000 mg weekly for 7 doses, followed 4 weeks later by 2000 mg every 4 weeks for 4 doses. Two units (approximately 200 or 250 ml) of FFP will be administered prior to ofatumumab(with the exception of the first dose). A unit of fresh frozen plasma is approximately 250ml (or half a pint).\n\nOfatumumab + Fresh Frozen Plasma","id":"OG000","title":"Ofatumumab + Fresh Frozen Plasma"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"Up to two weeks","title":"Percent Reduction in Complement Levels (CH50)","type":"SECONDARY","unitOfMeasure":"Percentage change"}